

Supplementary material

The supplementary material was provided by the authors and some information may not have been peer reviewed. Any opinions or recommendations discussed are solely those of the author(s) and are not endorsed by the Hong Kong Academy of Medicine and the Hong Kong Medical Association. The Hong Kong Academy of Medicine and the Hong Kong Medical Association disclaim all liability and responsibility arising from any reliance placed on the content.

Supplement to: SF Ngu, ANY Cheung, KK Jong, et al. 2024 Hong Kong College of Obstetricians and Gynaecologists Guidelines for cervical cancer prevention and screening. Hong Kong Med J 2024;Epub 3 Dec 2024. <https://doi.org/10.12809/hkmj2411547>.

Supplementary Table 1. Management of cytology results of normal and squamous lesions

Cervical cytology result	Suggested actions
NILM (normal cytology) [Fig 1]	<p>Cytology alone: repeat cytology every 3 years (after two initial annual screenings)</p> <p>Co-testing:</p> <p>If hrHPV-negative, repeat co-testing every 5 years</p> <ul style="list-style-type: none"> - If hrHPV-negative but with history of hrHPV positivity or abnormal cytology in the last screening, repeat screening (co-testing or cytology) in 3 years - If hrHPV-positive, choose from three options: <ul style="list-style-type: none"> o Repeat cytology every 6 months, three times o Repeat co-testing in 12 months o Conduct HPV16/18 genotyping <ul style="list-style-type: none"> ▪ If HPV 16/18-positive, refer for colposcopy ▪ If HPV 16/18-negative, repeat co-testing or cytology in 1 year, then in 3 years, then resume routine screening
Normal, transformation zone absent	<p>If age <30 y: manage as normal smears</p> <p>If age ≥30 y: perform HPV testing (preferred) or manage as normal smears</p>
ASCUS (Fig 3)	<p>Cytology alone: repeat cytology at 6 and 12 months</p> <p>HPV triage or co-testing:</p> <ul style="list-style-type: none"> - If hrHPV-positive, refer for colposcopy - If hrHPV-negative, repeat screening (co-testing or cytology) in 3 years
LSIL (Fig 4)	<p>Cytology alone: refer for colposcopy</p> <p>Co-testing:</p> <ul style="list-style-type: none"> - If hrHPV-positive, refer for colposcopy - If hrHPV-negative, repeat co-testing or cytology in 12 months <ul style="list-style-type: none"> o If any result is abnormal, refer for colposcopy o If result is normal, repeat co-testing or cytology in 3 years, then resume routine screening
ASC-H (including cases with coexisting LSIL) [online supplementary Fig 3]	<p>Refer for colposcopy</p> <ul style="list-style-type: none"> - Perform endocervical sampling if colposcopy results are unsatisfactory - If no pathology is identified, a review of materials is recommended <p>If no change in diagnosis, repeat cytology every 6 months or HPV test/co-testing annually</p> <ul style="list-style-type: none"> o If cytology result is normal for two consecutive 6-month intervals, resume routine screening o If two consecutive annual HPV test/co-testing results are normal, repeat HPV test/co-testing in 3 years, then resume routine screening

- Repeat colposcopy if abnormal cytology results persist or hrHPV positivity is observed
- Diagnostic excisional procedure is recommended if ASC-H persists for 2 years

HSIL	Refer for colposcopy <ul style="list-style-type: none"> - If there is no significant pathology to explain the source of abnormal cells, a review of materials is recommended. If no change in diagnosis, a diagnostic excisional procedure is recommended
------	--

Squamous cell carcinoma	Biopsy if visible growth is present; otherwise, arrange early referral for colposcopy and biopsy
-------------------------	--

Abbreviations: ASC-H = atypical squamous cells cannot rule out high-grade squamous lesion; ASCUS = atypical squamous cells of undetermined significance; HPV = human papillomavirus; hrHPV = high-risk human papillomavirus; HSIL = high-grade squamous intraepithelial lesion; LSIL = low-grade intraepithelial lesion; NILM = negative for intraepithelial lesion or malignancy

Supplementary Table 2. Management of cytology results of glandular lesions*

Cervical cytology result	Suggested actions
AGC-NOS (or atypical endocervical cells), AGC-FN and AIS	Refer for colposcopy, endometrial sampling, and endocervical sampling For AGC-FN and AIS: If no significant pathology can explain the source of abnormal cells, a diagnostic excisional procedure is recommended. Cold-knife conisation is preferred
Atypical endometrial cells	Perform endometrial and endocervical sampling If no endometrial pathology is identified, refer for colposcopy
Adenocarcinoma	Biopsy if visible growth is present; otherwise, arrange early referral for colposcopy, endometrial sampling, and endocervical sampling
Endometrial cells (in a woman aged ≥ 45 y)	Postmenopausal women: endometrial assessment is recommended Asymptomatic premenopausal women: no further investigation is required Offer endometrial assessment to those at increased risk of endometrial pathology, such as women with abnormal vaginal bleeding or obesity (body mass index ≥ 25 kg/m ²)

Abbreviations: AGC-FN = atypical glandular cells (favour neoplasia); AGC-NOS = atypical glandular cells (not otherwise specified); AIS = adenocarcinoma in situ


* Also refer to online supplementary Figure 2

Supplementary Table 3. Management of cytology results of others

Cervical cytology result	Suggested actions
Unsatisfactory	Cytology alone: repeat cytology in 2 to 4 months. If two consecutive cytology results are unsatisfactory, refer for colposcopy Co-testing: <ul style="list-style-type: none">- If HPV16/18-positive, refer for colposcopy- If other high-risk/untyped HPV-positive, repeat cytology in 2 to 4 months or refer for colposcopy- If HPV-negative, repeat cytology in 2 to 4 months. If two consecutive cytology results are unsatisfactory, refer for colposcopy
Other malignant neoplasms	Biopsy if visible growth is present; otherwise, arrange early referral for colposcopy and biopsy


Abbreviation: HPV = human papillomavirus

Supplementary Figure 1. Management after loop electrosurgical excision procedure




Abbreviations: ASC-H = atypical squamous cells cannot rule out high-grade squamous lesion; ASCUS = atypical squamous cells of undetermined significance; HPV = human papillomavirus; HSIL = high-grade squamous intraepithelial lesion; LEEP = loop electrosurgical excision procedure; LSIL = low-grade squamous intraepithelial lesion

Supplementary Figure 2. Management of cytology showing atypical glandular cells



Abbreviations: AGC = atypical glandular cell; AGC-FN = atypical glandular cells (favour neoplasia); AGC-NOS = atypical glandular cells (not otherwise specified); AIS = adenocarcinoma in situ; CIN = cervical intraepithelial neoplasia

Supplementary Figure 3. Management of cytology showing atypical squamous cells cannot rule out high-grade squamous lesion



* Irrespective of HPV genotyping results

Diagnostic excisional procedure if ASC-H persists at 2 years

Abbreviations: ASC-H = atypical squamous cells cannot rule out high-grade squamous lesion; CIN = cervical intraepithelial neoplasia; HPV = human papillomavirus